Global position paper on cardiovascular regenerative medicine.

Abstract

Based on the increasingly understood regenerative capacity of the human heart and vascular system,1 cardiovascular regenerative medicine (CRM) encompasses all potential diagnostic and therapeutic strategies aimed at restoring organ health. Envisioned to enhance the innate regenerative response of cardiovascular tissues, diverse and often complementary products and strategies have been investigated (e.g. stem and progenitor cells, stromal cells, extracellular vesicles such as microvesicles and exosomes, growth factors, non-coding RNAs, episomes and other gene therapies, biomaterials, tissue engineering products, and neo-organogenesis). Despite promising results based on 20 years of research, next generation CRM treatments have yet to transform cardiovascular practice.

Given the compelling need for a thorough critical debate on the past, present, and future of CRM, the international consortium Transnational AllianCe for regenerative Therapies In Cardiovascular Syndromes (TACTICS, www.tacticsalliance.org)2 summarizes the shared vision of leading expert teams in the field (for a complete list of TACTICS members please see Annex 1). The document addresses key priorities and challenges, including basic and translational research, clinical practice, regulatory hurdles, and funding sources. The methodological procedure included the following: (i) identification of strengths, weaknesses, opportunities, and threats (SWOT analysis) by means of an open poll; (ii) distribution of the main topics between at least two worldwide key opinion leaders, who prepared proposals for each topic; (iii) open discussion and consensus on each proposal between all members of TACTICS; and (iv) review of the document by an independent committee.